SANUWAVE Health Inc. (SNWV) is a publicly traded company in the Healthcare — Medical - Devices industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
SANUWAVE Health, Inc. is a shockwave technology company, which engages in the development and commercialization of patented noninvasive, biological response activating devices. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, helping to restore the body's normal healing processes and regeneration.
Analysis Summary
SANUWAVE Health Inc. reported revenue of $44.1M in the most recent fiscal year, growing at a 5-year CAGR of 61.1%.
Trailing-twelve-month margins: gross margin 75.2%, operating margin 1.5%, net margin 32.6%.
At the current price of $4.22, SNWV trades at a P/E of 2.53 and an ROE of 17.28%. Market capitalisation stands at $36M.
Balance sheet quality for SNWV: current ratio of 1.4, net debt of $11.0M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Cash flow quality is below average: free cash flow of $1.9M represents 16% conversion of reported net income. High conversion (above 90%) suggests earnings translate cleanly into cash; lower conversion may indicate working capital tightness or accounting timing differences.
Price
| Price | $4.22 |
| Market Cap | $36M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 2.53 |
| Price / Book | 13.02 |
| EV / EBITDA | 2.42 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 1728.10% |
| Return on Invested Capital | 2.80% |
| Return on Assets | 39.10% |
| Gross Margin | 75.20% |
| Operating Margin | 1.54% |
| Net Margin | 32.60% |
Financial Health
| Debt / Equity | 7.43 |
| Current Ratio | 1.28 |
| Piotroski F-Score | 6 |
| Altman Z-Score | -2.97 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| SNWV | SANUWAVE Health Inc. | $36M | 2.53 | 13.02 | 17.3% |
| ABT | Abbott Laboratories | $177.1B | 32.49 | 3.45 | 10.5% |
| 0Y6X.L | Medtronic Plc | $125.7B | |||
| MDT | Medtronic plc | $118.5B | 22.97 | 2.39 | 10.6% |
| SYK | Stryker Corporation | $109.2B | 29.95 | 4.66 | 16.4% |
| 0R2S.L | Stryker Corporation | $107.9B | 28.37 | 4.41 | 16.4% |
| 0HOY.L | Boston Scientific Corporation | $65.3B | 17.84 | 2.62 | 14.9% |
| BSX | Boston Scientific Corporation | $65.3B | 17.73 | 2.61 | 14.9% |
Price Performance
| 1 month | -16.10% |
| 3 months | -54.18% |
| Year-to-date | -85.86% |
| 1 year | -88.09% |
| 3 years | -44.98% |
| 5 years | -90.62% |
52-Week Range
| 52-week High | $40.87 |
| 52-week Low | $3.92 |
| Avg Volume (90d) | 165K |
Related companies: FHTX · HSDT · IMRX · INGN · MASS · NNOX · OM
Explore sector: Healthcare · Medical - Devices
More sections of SNWV: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks